Tab Application Banner
  • Users Online: 2632
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2011  |  Volume : 6  |  Issue : 2  |  Page : 55-60

Assessment of the efficacy of pulse Ibandronate therapy in non- steroidal anti-inflammatory drug refractory ankylosing spondylitis: An open prospective study


1 Professor, Department of General Medicine; Head, Rheumatology division, Department of General Medicine, Medical College, Kolkata, India
2 Post-graduate Trainee, Department of General Medicine, Medical College, Kolkata, India

Correspondence Address:
Rathindra Nath Sarkar
Professor, Department of General Medicine; Head, Rheumatology division, Department of General Medicine, Medical College, Kolkata
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


Rights and PermissionsRights and Permissions

Background: Amino-bisphosphonates like Pamidronate, having weak anti-Tumour Necrosis factor (TNF)-alpha property is effective in ankylosing spondylitis (AS). Objective: To assess the efficacy of intravenous pulse Ibandronate, another bisphosphonate, in non-steroidal anti- inflammatory drug (NSAID) refractory/intolerant AS, as it is cheaper, requires less frequent dosing and is easily available. Methods: Thirty-four patients, diagnosed as AS by Modified New York Criteria, having Bath AS Disease Activity Index (BASDAI) ≥ 4 (i.e. active disease) and NSAID refractory/intolerant, received six doses of injection Ibandronate (3 mg) intravenously, three monthly, for 15 months. Patients with peripheral arthritis were given sulfasalazine along with Ibandronate. Outcome assessed comparing baseline and final BASDAI, Bath AS metrology index (BASMI), Bath AS functional index (BASFI), Bath AS global score (BAS-G), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). Response defined according to assessments in ankylosing spondylitis (ASAS)-20 and BASDAI-50, and, reduction in tender and swollen joint counts in patients with peripheral arthritis. Results: Twenty-eight patients received all six doses. Twenty-one (75%) and 23 (82%) patients achieved BASDAI-50 and ASAS-20 responses, respectively. Significant reductions in mean BASDAI (48.36%), BASMI (55.08%), BASFI (47.03%), BASG (47.47%), ESR (49.24%) and CRP (66.38%) were noted after 15 months. Ten patients hav- ing peripheral joint involvement had significant decrement in swollen (67.74%) and tender (57.14%) joint counts. Conclusion: Intravenous Ibandronate has reasonable efficacy in the treatment of AS.


[PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed330    
    Printed9    
    Emailed0    
    PDF Downloaded76    
    Comments [Add]    

Recommend this journal